Pentosan Polysulfate

Pentosan polysulfate (PPS) is administered subcutaneously in clinical practice and has been evaluated in clinical trials via this route. The recommended dosing protocol is 125 mg per injection, with a maximum of 250 mg per week. The 125 mg dose is typically prepared in a 50 IU solution for subcutaneous injection.

As a harm-reduction strategy, the speaker recommends dividing the pentosan polysulfate dose into 25 IU aliquots administered to each gluteal area separately. This approach distributes injection trauma across multiple sites, reducing the risk of localized inflammatory reactions and fibrosis. The weekly maximum remains capped at 250 mg.

The speaker raises product sourcing and concentration as critical safety variables when adverse effects such as fibrosis are reported. Substandard or incorrectly concentrated compounded product is suggested as a potential contributing factor to adverse outcomes. Clinicians are advised to verify both the source and concentration of pentosan polysulfate before use.

Pentosan polysulfate has an anticoagulant component that can cause bruising and hematoma formation at injection sites. This anticoagulant-related bleeding may contribute to secondary fibroblast collagen deposition if injections are repeatedly administered to the same site. This is flagged as a distinct safety consideration separate from injection technique.

Failure to rotate injection sites with pentosan polysulfate is identified as a likely cause of reported fibrosis and irreversible scarring. Repeated injection trauma to the same anatomical area triggers local inflammatory reactions and secondary fibroblast collagen deposition. The speaker recommends strict site rotation to avoid this complication.